抗组胺药治疗特应性皮炎的系统综述与网络Meta分析
该系统综述与网络Meta分析纳入47项随机试验共6230例中重度特应性皮炎患者,评估加用口服抗组胺药的获益与风险。结果显示,加用H1抗组胺药可能轻微降低疾病严重度和瘙痒,但效应量低于最小重要差异,且第一代药物增加认知障碍风险。
要点
- 加用H1抗组胺药对特应性皮炎严重度和瘙痒的改善低于最小重要差异。
- 第一代抗组胺药可能增加认知障碍,并可能因不良事件增加治疗中断。
- 第二代抗组胺药认知障碍风险不同,氯雷他定风险最低。
核心结论
- 加用H1抗组胺药可能轻微降低特应性皮炎严重度和瘙痒,但效应量低于最小重要差异。
- 第一代抗组胺药增加认知障碍风险,并可能因不良事件增加治疗中断。
- 证据不支持特应性皮炎常规使用抗组胺药。
研究设计与样本
- 系统综述与随机试验网络Meta分析,检索截至2025年5月5日。
- 纳入47项随机试验,共6230例儿童和成人中重度特应性皮炎患者。
- 评估加用口服H1抗组胺药、H2阻滞剂、肥大细胞稳定剂或其组合。
主要发现
- 与安慰剂相比,加用第一代或第二代H1抗组胺药可能轻微降低特应性皮炎严重度(MD -1.87,95%CrI -3.47至-0.27)。
- 与安慰剂相比,加用H1抗组胺药可能轻微降低瘙痒严重度(MD -0.89,95%CrI -1.41至-0.37)。
- 所有研究干预可能不改善睡眠障碍或减少特应性皮炎急性加重(低确定性)。
- 第一代药物可能增加认知障碍,并可能因不良事件增加治疗中断(风险差每1000例增加66例,95%CrI 0至231)。
- 第二代药物认知障碍风险不同:氯雷他定每1000例增加0例,左西替利嗪增加16例,西替利嗪增加17例。
关键数值与推荐
- 特应性皮炎严重度采用oSCORAD评估(0-83,最小重要差异8.2,越低越好)。
- 瘙痒严重度采用数值评定量表(0-10,最小重要差异3,越低越好)。
- 第一代药物因不良事件治疗中断风险差为每1000例增加66例(95%CrI 0至231)。
临床怎么用
- 不推荐常规加用口服抗组胺药治疗特应性皮炎。
- 若考虑使用,应优先选择认知障碍风险较低的第二代药物如氯雷他定。
- 需权衡第一代药物的认知障碍和因不良事件停药风险。
局限性
- 研究间存在异质性,部分结果确定性为低或中等。
- 纳入患者主要为中重度特应性皮炎,结果可能不适用于轻度患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To systematically synthesise the benefits and harms of add-on oral antihistamines for managing atopic dermatitis (eczema). DESIGN: Systematic review and network meta-analysis of randomised trials. DATA SOURCES: Medline, Embase, CENTRAL, the United States Food and Drug Administration, and the European Medicines Agency databases from database inception to 5 May 2025. STUDY SELECTION: Randomised trials assessing add-on oral H1 antihistamines, H2 blockers, mast cell stabilisers (nedocromil sodium and sodium cromoglycate), or their combinations. Paired reviewers independently screened records, extracted data, and assessed risk of bias using a modified Cochrane Risk of Bias tool version 2. METHODS: Random effects bayesian meta-analyses synthesised atopic dermatitis severity (oSCORAD-objective scoring atopic dermatitis, 0-83; minimal important difference 8.2; lower better), itch severity (numerical rating scale, 0-10; minimal important difference 3; lower better), sleep disturbance, atopic dermatitis related quality of life, and harms. The network meta-analysis GRADE (Grading of Recommendations Assessment, Development and Evaluation) and Core GRADE approaches informed certainty of evidence ratings. RESULTS: 47 trials enrolled 6230 children and adults with primarily moderate to severe atopic dermatitis. With moderate certainty, compared with placebo, adding a first generation or second generation H1 antihistamine likely resulted in a small reduction in atopic dermatitis severity (mean difference -1.87, 95% credible interval -3.47 to -0.27) and itch severity (-0.89, -1.41 to -0.37). Although statistically detectable, these effects are well below established minimal important differences (smallest change in an outcome that a patient would identify as important). With low certainty, all studied interventions may not improve sleep disturbance or reduce atopic dermatitis exacerbations. First generation agents probably increase cognitive impairment and may increase treatment discontinuation because of adverse events (risk difference 66 more per 1000, 95% credible interval 0 to 231 more; moderate certainty). Second generation agents differ in their risk of cognitive impairment (range of mean effects 0 more per 1000 for loratadine, 16 more per 1000 for levocetirizine, and 17 more per 1000 for cetirizine). CONCLUSIONS: Among patients with atopic dermatitis, adding H1 antihistamines probably results in a clinically unimportant reduction in atopic dermatitis severity and itch severity, and may not reduce sleep disturbance or atopic dermatitis exacerbations. First generation agents increase cognitive impairment and may increase treatment discontinuation because of adverse events. Cognitive impairment risk differs among second generation agents. These findings provide evidence against routine antihistamine use in atopic dermatitis management and will inform updated clinical guidelines. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022345643.
引用
- Chu AWL, Wen A, Guyatt GH, et al. Antihistamines for atopic dermatitis (eczema): systematic review and network meta-analysis of randomised trials. BMJ. 2026. PMID: 42526949. doi:10.1136/bmj-2026-100163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。